Prevention of portal hypertension: From variceal development to clinical decompensation
Open Access
- 9 June 2014
- journal article
- review article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 61 (1) , 375-381
Abstract
Pharmacological treatment of portal hypertension (PH) has been exclusively devoted to gastroesophageal varices–related events at different frameworks, including prophylactic, emergency, or preventive therapy. The goals of treatment are to avoid the first bleeding episode, stop active bleeding, and prevent bleeding recurrence, respectively. The objective of preprimary prophylaxis (PPP) is to avoid variceal development, and therefore it necessarily deals with patients with cirrhosis at earlier stages of the disease. At these earlier stages, nonselective beta‐blockers (NSBBs) have been ineffective in preventing the development of varices and other complications of PH. Therefore, treatment should not rely on NSBB. It is possible that, at these earlier stages, etiological treatment of liver disease itself could prevent progression of PH. This review will focus mainly on early treatment of PH, because, if successful, it may translate into histological‐hemodynamic improvements, avoiding not only variceal development, but also other PH‐related complications, such as ascites and portosystemic encephalopathy. Moreover, the advent of new therapies may allow not only the prevention of the complications of PH, but also the chance of a substantial degree of regression in the cirrhotic process, with the possible prevention of hepatocellular carcinoma (HCC). (Hepatology 2015;61:375–381)Keywords
This publication has 31 references indexed in Scilit:
- The natural history of compensated HCV-related cirrhosis: A prospective long-term studyJournal of Hepatology, 2013
- New therapeutic paradigm for patients with cirrhosisHepatology, 2012
- Prognostic indicators of survival in patients with compensated and decompensated cirrhosisLiver International, 2012
- Beta-Blockers to Prevent Gastroesophageal Varices in Patients with CirrhosisNew England Journal of Medicine, 2005
- Portal HypertensionJournal of Clinical Gastroenterology, 2005
- A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosisGastroenterology, 2004
- Decreased fibrosis during corticosteroid therapy of autoimmune hepatitisJournal of Hepatology, 2004
- Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosisEuropean Journal of Gastroenterology & Hepatology, 1999
- Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: A 10-year prospective studyGastroenterology, 1996
- Prediction of the First Variceal Hemorrhage in Patients with Cirrhosis of the Liver and Esophageal VaricesNew England Journal of Medicine, 1988